# EDGAR Filing Document

**Accession Number:** 0002040475
**File Stem:** 0001213900-25-065839
**Filing Date:** 2025-7
**Character Count:** 3408
**Document Hash:** 3fd980532d6a815e21bee2ccb4696896
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-065839.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001213900-25-065839

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250718

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Drugs Made In America Acquisition II Corp.
- **CENTRAL INDEX KEY:** 0002040475
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** 954-870-3104

**MAIL ADDRESS:**
- **STREET 1:** 1 EAST BROWARD BOULEVARD
- **STREET 2:** SUITE 700
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

---

| | | |
|:---|:---|:---|
| ![](image_001.jpg) | G. Alex Weniger-Araujo<br> Partner<br>345 Park Avenue<br> New York, NY 10154 | **Direct** 212.407.4063<br> **Main** 212.407.4000<br> **Fax** 212.407.4990<br> aweniger@loeb.com |

---

July 18, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Manufacturing

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| Attention: | Ruairi Regan |
|  | Dorrie Yale |
|  | Babette Cooper |
|  | Isaac Esquivel |

---

---

| | |
|:---|:---|
| **Re:** | **Drugs Made In America Acquisition II Corp.** |
|  | **Amendment No. 1 to Draft Registration Statement on Form S-1** |
|  | **Submitted April 25, 2025** |
|  | **CIK No.: 0002040475** |

---

Ladies and Gentlemen:

On behalf of our client, Drugs Made In America Acquisition II Corp., a Cayman Islands exempted company (the "Company"), we respond to the comments of the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the "Staff") contained in the Staff's letter dated May 2, 2025 (the "Comment Letter") with respect to the above-referenced Draft Registration Statement on Form S-1.

Concurrent herewith, the Company is submitting via EDGAR the Registration Statement on Form S-1 (the "Registration Statement"), which reflects the Company's responses to the comments received by the Staff and certain updated information. For ease of reference, each comment contained in the Comment Letter is printed below and is followed by the Company's response. All page references in the responses set forth below refer to the page numbers in the Registration Statement.

**<u>Amended Draft Registration Statement on Form S-1</u>**

**<u>Conflicts of Interest, page 132</u>**

**1.** **We note your revised disclosure on page 133 regarding reimbursement of out-of-pocket expenses and repayment of loans, in response to prior comment 11. Please disclose the conflicts of interest relating to such arrangements in the event you do not complete a de-SPAC transaction.** 

**COMPANY RESPONSE:** In response to the Staff's comment, the Company has revised the disclosure on pages 134-135 of the Registration Statement.

Please do not hesitate to contact G. Alex Weniger-Araujo of Loeb & Loeb LLP at (212) 407-4063 with any questions or comments regarding this letter.

---

| |
|:---|
| Sincerely, |
| /s/ G. Alex Weniger-Araujo |
| G. Alex Weniger-Araujo |
| Partner |

---

cc: Lynn Stockwell, CEO